市場調查報告書

持續性腎功能替代療法市場 - 成長,趨勢,預測

Continuous Renal Replacement Therapy Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 925261
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
持續性腎功能替代療法市場 - 成長,趨勢,預測 Continuous Renal Replacement Therapy Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球持續性腎功能替代療法市場在2020年∼2025年間,預測將以7.2%的年複合成長率擴大。由於老年人口的增加和急性腎障礙的發生率,持續性腎替代療法的技術的進步,市場擴大。

本報告提供持續性腎功能替代療法的世界市場調查,市場概要,各類型,各地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊 。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各種模式
    • 持續性靜脈血液透析機 (CVVHD:Continuous Venovenous Hemodialysis)
    • 持續性靜脈血液過濾 (CVVH:Continuous Venovenous Hemofiltration)
    • 持續性靜脈血液過濾透析 (CVVHDF:Continuous Venovenous Hemodiafiltratio)
    • SCUF (Slow Continuous Ultrafiltration)
  • 各產品類型
    • 透析液、補充液
    • 拋棄式
    • 系統
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Asahi Kasei Medical Co., Ltd
    • B. Braun Melsungen AG
    • Baxter International, Inc.
    • Fresenius Medical Care AG & Co. KgaA
    • Infomed SA
    • Medica SpA
    • Medical Components, Inc
    • Medites Pharma Spol. SRO
    • Medtronic PLC
    • Toray Medical Co., Ltd

第7章 市場機會及未來趨勢

目錄
Product Code: 67727

The Continuous Renal Replacement Therapy Market is expected to register a CAGR of 7.2% during the forecast period. Continuous renal replacement therapy (CRRT) is commonly used in critically ill patients with acute kidney injury, particularly patients who are hemodynamically unstable to provide renal support.

Acute kidney injury (AKI) is a sudden episode of kidney damage or kidney failure that happens within a few hours or a few days. Acute kidney injury (AKI) results in build-up of waste products in blood and makes it hard for kidneys to keep the right balance of fluid in the body. Acute kidney injury (AKI) can also affect other organs such as the brain, heart, and lungs. Acute kidney injury generally common in patients who are in the hospital, in intensive care units, and especially in older adults. According to the International Society of Nephrology, every year approximately 13.3 million cases of acute kidney injury (AKI) globally, particularly high in emerging countries, where annual incidence is estimated to be 11.3 million. Increasing geriatric population and incidences of acute kidney injury, technological advancements in continuous renal replacement therapy are the key driving factors in continuous renal replacement therapy market.

Key Market Trends

Continuous Venovenous Haemofiltration Segment is Expected to Hold a Major Market Share in the Continuous Renal Replacement Therapy Market

  • Continuous Veno-Venous Hemofiltration (CVVH) is a temporary treatment for patients suffering with acute renal failure who are unable to tolerate hemodialysis and are unstable. With Continuous Veno-Venous Hemofiltration (CVVH), a dialysis catheter is placed in one of the main veins of the body.
  • According to International Society of Nephrology, Acute kidney injury (AKI) is experienced by 13.3 million patients every year globally and between 5.3 and 10.5 million people require dialysis or transplantation.
  • Continuous venovenous haemofiltration segment hold a significant market share in the continuous renal replacement therapy market and is anticipated to show similar trend over the forecast period due to high acceptance of continuous venovenous haemofiltration by nephrologists, because it is more feasible than the other modes and also incurs less complications than other modes of continuous renal replacement therapy.
  • Increasing geriatric population and incidences of acute kidney injury and technological advancements are the key driving factors in the continuous venovenous haemofiltration segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global continuous renal replacement therapy market due to rise in geriatric population and increasing incidences of acute kidney injury in this region. According to Centers for Disease Control and Prevention (CDC), approximately 30 million people or 15% of United States adults are estimated to have chronic kidney disease (CKD). chronic kidney disease (CKD) is estimated to be more common in women (16%) than in men (13%). Furthermore, high adoption rates of new technologies in continuous renal replacement therapy and the presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Continuous Renal Replacement Therapy Market is moderately fragmented competitive and consists of several major players. In terms of market share, few of the major manufacturers are currently dominating the capital equipment segment of the market. Some of the companies which are currently dominating the market are Asahi Kasei Medical Co., Ltd, B. Braun Melsungen AG, Baxter International, Inc, Fresenius Medical Care AG & Co. KgaA, Infomed SA, Medica SpA, Medical Components, Inc, Medites Pharma Spol. S.R.O, Medtronic PLC, and Toray Medical Co., Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Aging Population Increases Incidences of Acute Kidney Injury
    • 4.2.2 Technological Advancements in Continuous Renal Replacement Therapy
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 High Cost Associated Continuous Renal Replacement Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Mode
    • 5.1.1 Continuous Venovenous Hemodialysis
    • 5.1.2 Continuous Venovenous Hemofiltration
    • 5.1.3 Continuous Venovenous Hemodiafiltration
    • 5.1.4 Slow Continuous Ultrafiltration
  • 5.2 By Product Type
    • 5.2.1 Dialysate and Replacement Fluids
    • 5.2.2 Disposables
    • 5.2.3 Systems
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Asahi Kasei Medical Co., Ltd
    • 6.1.2 B. Braun Melsungen AG
    • 6.1.3 Baxter International, Inc.
    • 6.1.4 Fresenius Medical Care AG & Co. KgaA
    • 6.1.5 Infomed SA
    • 6.1.6 Medica SpA
    • 6.1.7 Medical Components, Inc
    • 6.1.8 Medites Pharma Spol. S.R.O
    • 6.1.9 Medtronic PLC
    • 6.1.10 Toray Medical Co., Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS